Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Further Reading from MarketBeat Media
3 Dividend Aristocrats Whose Yields Can Help Combat InflationWritten by Chris Markoch. Originally Published: 4/9/2026. 
Key Points
- Dividend Aristocrats including Amcor, Chevron, and AbbVie can provide reliable income streams that can help offset persistent inflation.
- Each of those three companies offers a yield above 3% combined with decades of consistent dividend growth, signaling strong financial stability.
- These stocks also provide exposure to defensive sectors like packaging, energy, and health care, which tend to perform well during periods of elevated inflation.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
The calendar says it’s spring, but investors may feel like it’s Groundhog Day: the same economic issues that have weighed on portfolios continue to persist. Just after a ceasefire between the United States and Iran was announced — a development that gave markets a tailwind — investors are now parsing fresh inflation readings that suggest inflation may be creeping higher again. The Personal Consumption Expenditures (PCE) index and the Consumer Price Index (CPI) for March are both out this week, and both reports are expected to show a modest uptick in inflation.
I Met Elon Musk "Face-to-Face"
During a private gathering of Wall Street elites, I was one of two people selected to speak with Elon personally.
As a result, my research now leads me to believe Elon will announce the SpaceX IPO on this date:
April 20, 2026. Circle it on your calendar.
I'm sharing an "access code" that lets anyone grab a pre-IPO stake before it happens. This is your invitation to the biggest wealth-building event of the decade. Click Here to See how to Get Your "SpaceX Access Code"
Worryingly, those readings don’t yet fully reflect the impact of higher oil prices, which tend to be inflationary. Whether that effect proves to be a short-term headwind or a longer-term problem remains to be seen. There are many layers to the inflation story. Even if oil prices fall, a stronger economy would raise demand, which can also be inflationary. Interest rates matter as well: the Federal Reserve has paused rate cuts, and a small but vocal group expects the next directional move for rates to be higher. Given this backdrop, inflation is unlikely to return to the Fed’s 2% target soon. One practical strategy is to buy dividend stocks yielding over 3%. Even if share prices don’t rise dramatically, dividend income and growing yields can help preserve real returns. Rather than simply chasing the highest yields, focus on companies with histories of consistently paying and reliably growing dividends. The three Dividend Aristocrats below have each increased payouts for at least 25 consecutive years, making them worthwhile candidates for income-oriented investors. Amcor Offers High Yield With Defensive DemandAmcor (NYSE: AMCR) is a global packaging company with market leadership across food and beverage, pharmaceutical, and personal care categories. Its products are consistently in demand, particularly when companies seek ways to reduce input costs. That said, Amcor’s stock hasn’t excited investors over the past year: AMCR is mostly flat over the last 12 months. Still, its dividend looks secure. The company has raised its payout for 27 consecutive years, a streak that includes dividend history inherited from the 2019 Bemis acquisition. As of April 9, the yield was 6.3%, with an annual payout of $2.60 per share. Amcor faces cost pressures from tariffs and higher oil prices. Trading around 27 times earnings, AMCR is relatively expensive versus its own history and the broader market. Still, the dividend appears well supported, and analysts have a consensus one-year price target of $52, which would imply a gain of more than 20% on top of the sizable yield. Chevron Combines Energy Exposure With Dividend StrengthEnergy stocks have been volatile since the late-February conflict with Iran began. Chevron (NASDAQ: CVX) has been one of the beneficiaries — year to date, CVX is up almost 30%. If oil stays elevated, Chevron owners will likely be rewarded. Even if oil prices retreat, Chevron remains a best-in-class oil major, increasing output not only in the United States but more recently in Venezuela. The integrated company also has substantial exposure to the growing liquefied natural gas market and strategic investments in renewable energy. The recent run-up in CVX’s price has made the stock appear a bit expensive in the short term. But the key is to keep a long-term perspective. Over time, Chevron has been a reliable steward of shareholder capital: in 2025 it generated $20.2 billion in free cash flow and returned a record $27 billion to shareholders through dividends and buybacks. Chevron’s dividend yields about 3.6%, equal to $7.12 per share annually. The company has raised its dividend for 38 consecutive years. AbbVie Delivers Reliable Growth and Income in Health CareHealth care isn’t usually touted as inflation protection, but demand for essential medicines tends to be durable: people don’t stop filling prescriptions when prices rise. That resilience is a key reason to consider AbbVie (NYSE: ABBV). For 2025, AbbVie reported record revenue of $61.2 billion, with immunology sales rising 14% driven by Skyrizi and Rinvoq. Those newer franchises have largely replaced revenue lost after Humira’s patent expiration. That recovery matters for the dividend story. After concerns that Humira’s patent loss might force a cut, ABBV has instead continued to increase payouts — a streak that now stretches to 52 years. The yield sits at about 3.3%, or $6.92 per share annually. AbbVie is more of a long-term hold than a trading idea; owning it and letting compounding work can be a powerful strategy. |
Post a Comment
Post a Comment